High absolute bioavailability of methylene blue given as an aqueous oral formulation (2008)

Peer-Reviewed Study · Ingeborg Walter-Sack, Jens Rengelshausen, Heike Oberwittler, Juergen Burhenne, Olaf Mueller, Peter Meissner, Gerd Mikus · September 23, 2008

Ingeborg Walter-Sack et al., 2008-09-23: Phase I randomised crossover trial in 16 healthy volunteers finding 72.3% absolute oral bioavailability of an aqueous methylene blue formulation, with chloroquine raising plasma concentrations.

The absolute bioavailability was 72.3 +/- 23.9%.

Abstract

Ingeborg Walter-Sack et al., 2008-09-23: Phase I randomised crossover trial in 16 healthy volunteers finding 72.3% absolute oral bioavailability of an aqueous methylene blue formulation, with chloroquine raising plasma concentrations. Phase I, open, randomised, intra-individual crossover study in 16 healthy volunteers, plus a randomised parallel-group comparison with chloroquine. Country: Germany (University of Heidelberg). Doses: 50 mg i.v. and 500 mg orally, one-week washout; chloroquine 750 mg orally alone or with 500 mg oral methylene blue. Route: i.v. and oral. Funder: 'Research Support, Non-U.S. Gov't' per the PubMed record. Conflicts: none declared. Comparator: i.v. versus oral in the same subject; chloroquine alone versus combined. AUC 7,639 ng/mL*h i.v. vs 51,171 ng/mL*h oral at a 1:10 dose ratio; 76,897 ng/mL*h with chloroquine. Recorded against MTJ-24, which found far lower oral exposure – the two studies used different formulations and matrices, and the contradiction is left standing. Also filed as MTF-07, MTF-19 (claims C1, C4, C5). Study type: randomized trial.